Published date: 27 November 2023

Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.


Approach to market date: 15 January 2024

Contract summary

Industry

  • Immune sera and immunoglobulins - 33651500

  • Vaccines - 33651600

Location of contract

United Kingdom

Value of contract

£0

Procurement reference

CF-1989400D0O000000rwimUAA

Published date

27 November 2023

Approach to market date

15 January 2024

Contract start date

1 July 2024

Contract end date

30 June 2028

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

The provision of immunisation products indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) lower respiratory tract disease
The contracting authority estimates their requirement for deliveries between 1 July 2024 to 30 June 2026 ('Initial Term') of the contract to be up to 1.6 million doses for Lot 1, up to 1.69 million doses for Lot 2, up to 1.45 million doses for Lot 3 or up to 4 million doses for Lot 4, with the option to extend for up to an additional 24 months.

More information

Attachments

About the buyer

Contact name

Chantal Jockel

Address

10 South Colonnade
London
E14 4PU
GB

Email

chantal.jockel@ukhsa.gov.uk